VIVUS Inc. (VVUS)

4.31
0.16 3.86
NASDAQ : Health Technology
Prev Close 4.15
Open 4.15
Day Low/High 4.15 / 4.38
52 Wk Low/High 2.15 / 6.41
Volume 105.41K
Avg Volume 101.50K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 43.85M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Orexigen 3rd-quarter Loss Narrows On Lower Costs

Orexigen 3rd-quarter Loss Narrows On Lower Costs

Orexigen Therapeutics' 3rd-quarter loss narrows on lower costs following Contrave studies

Oil, Retirement, Gold and Baseball

Oil, Retirement, Gold and Baseball

Gregg Greenberg hosts. Guests include Tim Guinness, portfolio manager for the Guinness Atkinson Global Energy Fund, Lynne Ford, head of retail retirement for Wells Fargo, David Peltier, TheStreet.com's Stocks Under $10 portfolio manager and Richard Peterson, Director of Credit, Markets and Risk for S&P.

Earnings Roundup: GMAC, Molson Coors

Earnings Roundup: GMAC, Molson Coors

Earnings roundup: GMAC loss narrows as auto lending profitable, Molson Coors profit grows

Vivus Shares Dive Following 3rd-quarter Report

Vivus Shares Dive Following 3rd-quarter Report

Vivus shares dive after 3rd-quarter report, but Wall Street remains focused on obesity drug

Amylin Makes Obesity Drug Deal: BioBuzz

Amylin Makes Obesity Drug Deal: BioBuzz

Japanese drugmaker Takeda licenses worldwide rights to Amylin weight-loss pipeline.

Amylin Signs Weight-loss Drug Deal With Takeda

Amylin Pharmaceuticals signs weight-loss drug deal with Takeda potentially worth over $1B

Vivus, Analyst in Obesity Drug Side-Effect Spat

Vivus, Analyst in Obesity Drug Side-Effect Spat

At issue are cognitive side effects for Vivus' weight-loss drug Qnexa

Cramer's 'Mad Money' Follow-Up: Oct. 27

Here's how some of Monday's 'Mad Money' stocks fared on Tuesday.

'Mad Money Lightning Round': Bank With Huntington Bancshares

Cramer says it's a terrific bank that is favored by regulators.

Cramer's 'Mad Money' Recap: Market Worries (Final)

Cramer said the Dow cannot rally past 10,000 without a solid improvement in earnings. Click for news from Jim Cramer.

'Mad Money Lightning Round': Stick With 3M

'Mad Money Lightning Round': Stick With 3M

Cramer calls it one of the great telecom stocks.

Cramer's 'Mad Money' Recap: Your Chance to Buy Apple (Final)

Cramer's 'Mad Money' Recap: Your Chance to Buy Apple (Final)

Cramer says investors can take advantage of a production glitch in iPhones to buy Apple on Tuesday, the day after its earnings report. Click for news from Jim Cramer.

Biotech Mailbag: Transdel Pharma

Biotech Mailbag: Transdel Pharma

Readers touch base with Adam on Transdel Pharma, Vivus, Genta, Cel-Sci and more.

Cramer's 'Mad Money' Recap: How to Play Next Week's Market (Final)

Cramer's 'Mad Money' Recap: How to Play Next Week's Market (Final)

Stick with the stocks that have already told us they're doing well, and watch out for the battle of macro economic data: retail sales vs. jobless. Click for news from Jim Cramer.

Orexigen, Vivus Shares Rise On Obesity Drug Data

Orexigen, Vivus Shares Rise On Obesity Drug Data

Orexigen Therapeutics, Vivus shares gain ground on obesity drug study data

Onyx Pharma Holds Conference Call Too Late: BioBuzz

Onyx Pharma Holds Conference Call Too Late: BioBuzz

Why wait one week to discuss good breast cancer data?

Biotech Calendar: Key Dates and Events

Biotech Calendar: Key Dates and Events

A quick and dirty guide to important biotech events for October.

Orexigen's Obesity Drug Empatic Meets Study Goal

Orexigen's Obesity Drug Empatic Meets Study Goal

Orexigen Therapeutics' obesity drug candidate meets weight loss goal in midstage study

Orexigen Moves Forward With 2nd Obesity Drug: BioBuzz

Orexigen Moves Forward With 2nd Obesity Drug: BioBuzz

A midstage study of Empatic demonstrates significant weight loss.

Sector Snap: Trio Of Obesity Drug Makers

Sector Snap: Trio Of Obesity Drug Makers

After Arena report, Arena and Virus shares rise as analysts assess prospects for obesity drugs

Arena Obesity Drug Falls Short Against Other Meds

Arena Obesity Drug Falls Short Against Other Meds

Arena weight drug lorcaserin meets goals, but comes up short against rival drug candidates

Arena Drug Aids Weight Loss, a Little

Arena Drug Aids Weight Loss, a Little

Patients taking lorcaserin lost a placebo-adjusted 3.1% of their body weight after one year. But that stat falls short of the 5% placebo-adjusted weight loss benchmark that many doctors believe is clinically meaningful.

Psst... These Drug Firms Are Getting Bought: BioBuzz

Psst... These Drug Firms Are Getting Bought: BioBuzz

Big Pharma is seeking deals with biotech, specialty pharma, analyst says

Arena Falls After Downgrade On Obesity Drug View

Arena Falls After Downgrade On Obesity Drug View

Analyst thinks sales of Arena's lorcaserin will trail other obesity drugs, downgrades stock

Dueling Views of Arena Pharma: BioBuzz

Dueling Views of Arena Pharma: BioBuzz

Bulls and bears prepare for Arena Pharma's obesity drug trial results.

Vivus CEO Sells $2.2M Worth

Vivus CEO Sells $2.2M Worth

Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.

Biotech Stock Mailbag: Genta Takes Another Stab

Biotech Stock Mailbag: Genta Takes Another Stab

Readers weigh in on Genta, Opexa, Osiris, Vivus and Antigenics.

Today's Lists at Stockpickr: Sept. 9

Here's what stood out in the market today.

EBay, McDonald's, Capital 1, Apple Big Movers

EBay, McDonald's, Capital 1, Apple, Popular are among big market movers

Stocks Extend Rally

Stocks Extend Rally

Stocks finish modestly higher Wednesday as Steve Jobs takes the Apple stage but fall off their highs after the Fed's beige book.

TheStreet Quant Rating: D (Sell)